Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Legend Biotech CorporationNASDAQ: LEGN

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin dips below year-ago levels

Q3 FY2026 selling, general & admin of $69.8M fell 20.1% year over year, behind the +10.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 27.6% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Selling, general & admin amounted to 33.2% of revenue in FY2025, down 12.1 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $1.47B (+331.4%) for the fiscal year ending Dec 2026, a step up from the +20.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$69.8M-27.6% QoQ
Last fiscal yearDec 2025
$341.6M+20.2% YoY
LTMSep 2026
$357.49M+10.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.1%+287.1%+307.2 pp
1 year+20.2%+331.4%+311.2 pp
3-year CAGR+25.2%+78.6%+53.4 pp
5-year CAGR+47.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
341.6M USD
Year-over-year change
+20.2%
4-year CAGR
+22.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 selling, general & admin of $357.49M is the highest of the 11 companies compared; the peer median is $33.37M.
  • Its year-over-year change of +10.5% is the 3rd highest of 11, against a peer median of -12.6%.
  • Selling, general & admin amounts to 26.3% of revenue for LEGN, versus a peer median of 238.6%.
LEGN Competitors Peer median
Selling, General & Admin for LEGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M +10.5%+25.2%26.3%
AUTLAutolus Therapeutics plcLTM Mar 2026$142.24M +17.3%+60.5%153.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M -11.2%-10.5%—
FATEFate Therapeutics, Inc.LTM Mar 2026$42.34M -49.3%-18.0%670.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M -22.7%-27.3%131109.7%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M -1.5%-0.1%323.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$30.49M -13.9%-7.9%67.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$30.27M +4.4%+9.7%1705.2%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$22.18M -32.4%-9.0%—
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$17.8M -55.8%-27.2%76.9%
CLLSCellectis S.A.LTM Mar 2026$9.18M +20.3%-1.1%13.5%
Peer median (excluding LEGN) $33.37M-12.6%-8.5%238.6%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.